The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Aratana Therapeutics Inc. | Common | 03874P101 | 1,533 | 250,000 | SH | SOLE | 250,000 | 0 | 0 | ||
| Chiasma, Inc. | Common | 16706W102 | 17,840 | 5,736,296 | SH | SOLE | 5,736,296 | 0 | 0 | ||
| Conatus Pharmaceuticals, Inc. | Common | 20600T108 | 4,264 | 2,464,807 | SH | SOLE | 2,464,807 | 0 | 0 | ||
| Proteon Therapeutics, Inc. | Common | 74371L109 | 2,232 | 983,381 | SH | SOLE | 983,381 | 0 | 0 | ||
| Rhythm Pharmaceuticals, Inc. | Common | 76243J105 | 82,653 | 3,074,893 | SH | SOLE | 3,074,893 | 0 | 0 | ||
| Syndax Pharmaceuticals, Inc. | Common | 87164F105 | 9,651 | 2,168,691 | SH | SOLE | 2,168,691 | 0 | 0 | ||